101. The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens.
- Author
-
Viswanathan K, Siddiqui MT, and Borczuk AC
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Biopsy, Fine-Needle, Carcinoid Tumor diagnosis, Carcinoid Tumor metabolism, Carcinoid Tumor pathology, Carcinoid Tumor surgery, Carcinoma, Giant Cell pathology, Carcinoma, Giant Cell surgery, Carcinoma, Large Cell diagnosis, Carcinoma, Large Cell metabolism, Carcinoma, Large Cell pathology, Carcinoma, Large Cell surgery, Carcinoma, Neuroendocrine diagnosis, Carcinoma, Neuroendocrine metabolism, Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine surgery, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Carcinosarcoma pathology, Carcinosarcoma surgery, Female, Humans, Immunohistochemistry, Lung metabolism, Lung pathology, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Middle Aged, Pulmonary Blastoma pathology, Pulmonary Blastoma surgery, Retrospective Studies, Small Cell Lung Carcinoma diagnosis, Small Cell Lung Carcinoma metabolism, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma surgery, Carcinoma, Giant Cell diagnosis, Carcinoma, Giant Cell metabolism, Carcinosarcoma diagnosis, Carcinosarcoma metabolism, Cytodiagnosis methods, Lung Neoplasms diagnosis, Lung Neoplasms metabolism, Pulmonary Blastoma diagnosis, Pulmonary Blastoma metabolism, Zinc Finger E-box-Binding Homeobox 1 metabolism
- Abstract
Objective: Although uncommon, pulmonary sarcomatoid carcinoma carries a worse prognosis due to poor chemotherapeutic response. Currently, a histologic spindle and/or giant cell component indicates sarcomatoid differentiation, with zinc E-box binding homeobox 1 (ZEB1) implicated in promoting epithelial-mesenchymal transition. However, diagnostic use of ZEB1 in limited specimens, including cell block (CB) preparations, remains unclear., Materials and Methods: Pulmonary sarcomatoid (SARC, n = 15), typical (TC, n = 10) and atypical carcinoid (AC, n = 10), small cell (SCLC, n = 8) and large cell neuroendocrine carcinoma (LCNEC, n = 9), squamous cell carcinoma (SQ, n = 7), and adenocarcinoma (ADC, n = 7) CBs along with 69 SARCs, 20 TCs, 21 ACs, 9 SCLCs, 10 LCNECs, 71 SQs, 402 ADCs, 16 large cell carcinoma (LCC) and 17 other thoracic tumor (OT) surgical specimens between 2007 and 2018 were retrieved. ZEB1 (Sigma Aldrich, St. Louis, Mo and Novus Biological, Centennial, Colo) immunohistochemistry was graded 1+ to 3+, with ≥1+ and >5% staining considered positive., Results: Nuclear ZEB1 was seen in 80% SARC (12/15), 0% TC (0/10), 0% AC (0/10), 12.5% SCLC (1/8) and 11.1% LCNEC (1/9), 0% SQ (0/7), and 0% ADC (0/7) CBs. In surgical specimens, 75.4% SARCs (52/69), 0% TCs (0/20), 0% ACs (0/21), 11.1% SCLCs (1/9), 30% LCNECs (3/10), 0% SQs (0/71), 0.2% ADCs (1/402), 12.5% LCCs (2/16), and 11.8% OTs (2/17) demonstrated ZEB1. ZEB1 sensitivity and specificity in cytology and surgical specimens were 80% and 96.1%, and 75.4% and 98.1%, respectively., Conclusions: ZEB1 is sensitive and highly specific for pulmonary sarcomatoid carcinoma in limited cytologic and surgical specimens. Diagnostic pitfalls include high-grade neuroendocrine tumors and large cell carcinoma, which are resolvable by morphologic considerations., (Copyright © 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF